#USA #Somerville #Matterworks #Machine Intelligence #Predictive Biology

Matterworks Inc. Secures Series A Funding for Machine Intelligence

Matterworks, Inc., a pioneering company in the realm of predictive biology, has recently announced its successful Series A funding round. This pivotal development was made public on June 3, 2025, as the company aims to further harness unstructured molecular data and advance the capabilities of machine intelligence in the biological sciences.

Led by esteemed investment firms Lewis Clark Partners and OMX Ventures, the funding round also saw contributions from prominent investors such as Pillar VC, Germin8 Ventures, Intermountain Ventures, and Tarsadia. Together, they have provided Matterworks with the financial backing needed to scale its innovative machine learning operations and enhance its model-as-a-service (MaaS) framework.

In a statement regarding this funding round, Jack Geremia, CEO and Co-Founder of Matterworks, expressed his excitement about the partnership with Lewis Clark. He stated, "I am delighted to partner with Lewis Clark and welcome Carolyn Fritz to the Company's Board of Directors as we accelerate machine intelligence innovations that tackle the unsustainable cost of life science R&D." His acknowledgment of the escalating challenges within life science research underlines the critical role of advanced AI technologies in overcoming such obstacles.

Highlighting the transformative potential of Matterworks' AI platform, Carolyn Fritz, Operating Partner at Lewis Clark Partners, remarked, "In collaboration with its customers, Matterworks has repeatedly demonstrated its AI platform provides a step change reduction in the cost and throughput of mass spec quantitation. We are excited to partner with this team in accelerating commercialization of their transformational technology." This collaboration aims not only to enhance the company's systems but also to make impactful contributions to the broader biotech landscape.

Craig Asher, Managing Director from OMX Ventures, further emphasized the importance of Matterworks' innovations in the industry. He stated, "Matterworks is leveraging AI to unlock a new data layer for biology by making mass spectrometry accessible to all biologists. It's a shift as transformative as single-cell sequencing, and we are thrilled to support this exceptional team." This insight sheds light on the potential implications of Matterworks’ technologies in democratizing access to advanced biological research tools.

Matterworks' flagship offering, the Large Spectral Models (LSMs), is a testament to its innovative approach. The LSMs provide a self-supervised machine intelligence platform capable of interpreting molecular-omic data. In 2024, the company introduced Pyxis™, a pioneering generative AI solution that facilitates comprehensive untargeted molecular annotation. Pyxis™ represents a significant leap in the ability to analyze complex biological data and predict outcomes, which could revolutionize the field of predictive biology.

About Matterworks

Founded with a vision to redefine predictive biology, Matterworks stands at the forefront of advancements in the intersections of AI and biotechnology. Its commitment to unlocking the value hidden within molecular data is evidenced by its cutting-edge solutions that promise to streamline research processes and enhance the understanding of biological systems.

About Lewis Clark Partners

Based in St. Louis, Lewis Clark Partners is an investment firm dedicated to backing innovative companies that lead the way in science, health, food, and agricultural advancements. With a focus on growth-stage companies, their team brings extensive sector expertise to drive national and global scaling efforts.

About OMX Ventures

OMX Ventures is focused on pioneering investments in bioengineering, aiming to fuel innovation across various domains including therapeutics, diagnostic tools, and synthetic biology platforms. Their commitment to aligning with firms at the intersection of biology and AI positions them as leaders in the venture capital landscape.

In summary, Matterworks’ recent funding acquisition marks a significant milestone in the journey towards advancing machine intelligence capabilities within the life sciences. By leveraging this funding, Matterworks is set to enhance its innovative solutions, providing an essential resource for biologists and paving the way for future breakthroughs in predictive biology.